Business Wire

Duetti Secures $200 Million to Scale Independent Music Catalog Acquisitions and Enhance Platform Capabilities

21.1.2026 14:01:00 CET | Business Wire | Press release

Share

Funding Led by a $50 Million Series C Equity Investment from The Raine Group

Duetti Inc. (“Duetti” or the “Company”), the music-tech and financial services company that empowers independent music creators to unlock the value of their music catalogs, today announces it has secured $200 million in new funding to accelerate music catalog acquisitions and expand its technology and services globally. The financing is led by a $50 million Series C equity investment by Raine Partners, the flagship growth equity fund of The Raine Group, alongside a second $125 million private securitization and a $25 million increase of an existing credit facility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121033285/en/

In over three years, Duetti has raised over $635 million, including over $100 million in equity, to support the global independent music community. To date, the Company has partnered with more than 1,100 artists, songwriters, and other music creators across 40+ countries to purchase and manage portions of their music rights catalogs.

The Series C equity investment from Raine Partners enables Duetti to strengthen its leadership in music rights acquisition by investing in its team and platform. The funds will be used to expand Duetti’s technology infrastructure, enhance marketing services, and grow its global presence. Duetti is experiencing rapid growth, currently signing 80+ deals each month (over 2.5x the monthly rate one year ago), on the back of its expansion into publishing rights, in addition to master recording rights, and its growing global footprint. In connection with the equity financing, Joe Puthenveetil, Partner at The Raine Group, will join the Duetti Board of Directors.

Duetti has a 65-person team operating across New York City, Los Angeles, Miami, Nashville, London, and Rio de Janeiro. Over 30% of Duetti’s 2025 deals originated from outside the US, from international markets such as France, the United Kingdom, Germany, Brazil, and Mexico. The Company also provides marketing and catalog management services - including playlisting through a network of 3,000+ playlists with 5+ million followers across DSPs, remix production with 60+ releases per quarter, sync licensing, and 200+ customized artist marketing programs in 2025.

"The traditional music industry and the financially driven catalog buyout funds are not able to keep pace and adapt their infrastructure to the explosive growth of the independent music sector," said Lior Tibon, CEO and Co-Founder of Duetti. "This new funding allows us to continue building proprietary databases and systems to identify, predict, and effectively manage and support music catalogs of independent creators, the fastest growing and most exciting segment of the industry.”

“We are excited to partner with Lior and team as they develop a next-generation music company that empowers independent creators. Duetti has democratized the industry by enabling artists at every stage of their careers to monetize their rights and access the marketing and growth resources offered by a modern label and publisher,” said Joe Puthenveetil and Fred Davis, partners at The Raine Group.

Duetti completed its second private asset-backed securitization of $125 million, bringing its existing master trust total to $205 million. The Company plans to continue accessing the securitization market regularly, tapping an efficient and liquid source of financing while providing investors exposure to fast-growing segments of the music market. In Q4 2024, Duetti pioneered the first-ever music securitization transaction primarily backed by independent artists' catalogs, and intends to continue innovating through efficient new financing structures for these catalogs.

“Working with Duetti gave me clarity and confidence around how to think about my music as an asset,” said Calimossa, the Los Angeles-based artist and producer. “They respect that every artist’s journey is different and took the time to walk me through real options I could align with my long-term goals. Beyond that, they showed up as true partners, supporting my music through marketing, sync opportunities, and career guidance. That level of trust and continued support is what allows independent artists like me to build something sustainable for the future.”

KEEP UP WITH DUETTI

WEBSITE | INSTAGRAM | FACEBOOK | LINKEDIN

About Duetti

Duetti is a music finance and services platform that partners with independent artists and creators. Founded in 2022 by CEO Lior Tibon and COO Christopher Nolte, Duetti provides capital and operational support to help creators monetize, manage, and grow their music catalogs.

Through flexible deal structures, Duetti works with a broad range of music creators and supports them with catalog management and marketing services. Since its founding, Duetti has partnered with more than 1,100 creators across over 40 countries.

Duetti is backed by The Raine Group, Flexpoint Ford, Nyca Partners, Viola Ventures, and Roc Nation, and has raised more than $635 million to date through a combination of equity and debt financing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121033285/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the

Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release

Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release

New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye